+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Portola Pharmaceuticals LLC - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 23 Pages
  • June 2022
  • GlobalData
  • ID: 5626578
Portola Pharmaceuticals LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The publisher's summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights


Portola Pharmaceuticals LLC (Portola Pharmaceuticals) is a biopharmaceutical company that discovers, and develops therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company's products portfolio include Betrixaban, an oral once-daily Factor Xa inhibitor anticoagulant that inhibits the activity of Factor Xa; andexanet alfa, a recombinant protein designed to reverse anticoagulant activity of both direct and indirect Factor Xa inhibitors; and cerdulatinib, an oral, dual Syk-JAK inhibitor in development to treat hematologic cancers. Portola Pharmaceuticals provides compounds using biomarker and genetic approaches for clinical, regulatory and commercial purpose of life-saving therapies therapies. The company works in collaboration with other pharmaceutical and biotechnology companies for the clinical development of its lead candidates. Portola Pharmaceuticals is headquartered in South San Francisco, California, the US.

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the publisher's detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Portola Pharmaceuticals LLC - Key Facts
  • Portola Pharmaceuticals LLC - Key Employees
  • Portola Pharmaceuticals LLC - Key Employee Biographies
  • Portola Pharmaceuticals LLC - Major Products and Services
  • Portola Pharmaceuticals LLC - History
  • Portola Pharmaceuticals LLC - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Portola Pharmaceuticals LLC - Business Description
  • R&D Overview
  • Portola Pharmaceuticals LLC - SWOT Analysis
  • SWOT Analysis - Overview
  • Portola Pharmaceuticals LLC - Strengths
  • Portola Pharmaceuticals LLC - Weaknesses
  • Portola Pharmaceuticals LLC - Opportunities
  • Portola Pharmaceuticals LLC - Threats
  • Portola Pharmaceuticals LLC - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Portola Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Portola Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Portola Pharmaceuticals LLC, Recent Deals Summary
Section 4 - Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Portola Pharmaceuticals LLC, Key Facts
  • Portola Pharmaceuticals LLC, Key Employees
  • Portola Pharmaceuticals LLC, Key Employee Biographies
  • Portola Pharmaceuticals LLC, Major Products and Services
  • Portola Pharmaceuticals LLC, History
  • Portola Pharmaceuticals LLC, Subsidiaries
  • Portola Pharmaceuticals LLC, Key Competitors
  • Portola Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Portola Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Portola Pharmaceuticals LLC, Recent Deals Summary
List of Figures
  • Portola Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Portola Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Xencor Inc
  • SELLAS Life Sciences Group Inc
  • Rocket Pharmaceuticals Inc
  • KemPharm Inc